Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23945272 | 0.84 | KDM4E (0.53) | CYP2C19EPHX2 | |
| SCHEMBL21106780 | 0.84 | CYP2C19 (0.41) | CYP2C19EPHX2TSHR | |
| SCHEMBL20234764 | 0.83 | CYP2C19 (0.39) | CYP2C19EPHX2TSHREPHX1 | |
| SCHEMBL22856128 | 0.81 | MEN1 (0.53) | CYP2C19EPHX2 | |
| SCHEMBL18611819 | 0.81 | CYP2C19 (0.38) | CYP2C19EPHX2EPHX1 | |
| SCHEMBL23696036 | 0.80 | CYP2C19 (0.38) | CYP2C19EPHX2TSHREPHX1 | |
| SCHEMBL22790738 | 0.80 | MEN1 (0.52) | CYP2C19EPHX2TSHR | |
| SCHEMBL24673615 | 0.80 | CYP2C19 (0.38) | CYP2C19EPHX2TSHREPHX1MAPT | |
| SCHEMBL21105474 | 0.79 | KMT2A (0.46) | CYP2C19EPHX2TSHRMAPTHSD17B10 | |
| SCHEMBL23945685 | 0.79 | SMN1; SMN2 (0.44) | CYP2C19EPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |